Access to Advanced Health Institute

Top Programs

By expenditures

• Multivalent Flavivirus Vaccine Development Using a Flexible Replication RNA Platform

  93.RD

  $5.56M
• Multivalent Flavivirus Vaccine Development Using A Flexible Replication Rna Platform

  93.RD

  $3.39M
• Advanced Development and Clinical Evaluation of a Synthetic Intranasal Entamoeba Histolytica Vaccine Containing Adjuvant

  93.RD

  $2.68M
• Development of Vaccine Candidates for Biodefenses, AMR Infections and Emerging Infectious Diseases

  93.RD

  $2.65M
• Multivalent Flavivirus Vaccine Developmentusing A Flexible Replication Rna Platform

  93.U04

  $1.98M
• Advanced Development and Clinical Evaluation of A Synthetic Intranasal Entamoeba Histolytica Vaccine Containing Adjuvant

  93.RD

  $1.27M
• Advanced Development and Clinical Evaluationof A Synthetic Intranasal Entamoeba Histolytica Vaccine Containing Adjuvant

  93.U03

  $706,516
• Adjuvant Discovery Program

  93.U02

  $538,734
• Development of Vaccine Candidates for Biodefenses, Amr Infections and Emerging Infectious Diseases

  93.RD

  $464,856
• Military Medical Research and Development

  12.420

  $168,790
• MILITARY MEDICAL RESEARCH AND DEVELOPMENT

  12.420

  $101,046
• Adjuvant Discovery Program

  93.RD

  $94,844
• Allergy and Infectious Diseases Research

  93.855

  $59,251
• Allergy, Immunology and Transplantation Research

  93.855

  $48,024
• ALLERGY AND INFECTIOUS DISEASES RESEARCH

  93.855

  $18,488